Compare DBL & CNXU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DBL | CNXU |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.5M | 282.3M |
| IPO Year | 2011 | N/A |
| Metric | DBL | CNXU |
|---|---|---|
| Price | $14.03 | $7.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 71.9K | ★ 118.4K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | ★ 8.67% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.95 | $7.30 |
| 52 Week High | $16.01 | $13.66 |
| Indicator | DBL | CNXU |
|---|---|---|
| Relative Strength Index (RSI) | 40.18 | 32.40 |
| Support Level | $13.95 | N/A |
| Resistance Level | $14.42 | $11.45 |
| Average True Range (ATR) | 0.09 | 1.29 |
| MACD | -0.01 | -0.20 |
| Stochastic Oscillator | 37.84 | 6.40 |
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.
Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings. The company focuses durable, and growing addressable markets in regenerative aesthetics, wound care, 3D-printed tissue structures, veterinary wound repair, and dental soft-tissue regeneration.